GMP Speed Case Study — PAN-Biotech
GMP Speed · Case Study

50,000 Litres of GMP Supply, Delivered in Under Five Weeks

When a vaccine manufacturer needed large-volume GMP supply on a timeline measured in weeks, PAN-Biotech quoted in three days and delivered ~50,000 litres in under five weeks — at GMP quality.

3 daysto a firm quote
16 Novfirst order
8 Decfirst production
20 Decfirst delivery
~50,000 Ldelivered
< 5 wksproduction → completion
Customer
A vaccine manufacturer facing an urgent, large-volume production need (anonymised)
Challenge
A rapid GMP supply requirement on a timeline measured in weeks, not months
Solution
Fast-track GMP manufacturing — quote in 3 days; first delivery within two weeks of production start
Result
~50,000 L delivered in under 5 weeks (first production to completion)
50,000 L in under 5 weeks Oct Enquiry — urgent,large-volume need 16 Nov First order(quote in 3 days) 8 Dec First production(3 weeks later) 20 Dec First delivery(< 2 weeks) 10 Jan ~50,000 Lcomplete

The challenge

In October, a vaccine manufacturer approached PAN-Biotech with an urgent, large-volume production need. The timeline was measured in weeks, not months — every week of delay put their own programme at risk. They needed a GMP partner who could quote, qualify and produce at speed.

The turnaround

PAN-Biotech returned a convincing quote within three days. The first order followed on 16 November; first production began on 8 December — three weeks later — and the first delivery went out on 20 December, in under two weeks. By 10 January, ~50,000 litres had been delivered — in under five weeks from first production, at GMP quality.

Why it works

  • Speed is the product — when a manufacturer's timeline is measured in weeks, a 3-day quote and a 5-week delivery are the difference between staying on schedule and slipping.
  • GMP without the wait — ~50,000 L at GMP quality, produced inside three weeks of the order and delivered inside two weeks of production start.
  • Scale on demand — large-volume GMP supply, drawn from validated processes and EU Annex 1 manufacturing.
Customer anonymised. Published on the CMO/CDMO/OEM page. © 2026 PAN-Biotech.